Report from the extra general meeting
At the extra general meeting (EGM) in ChronTech Pharma AB (below ”the Company”) on the 16th of May it was resolved to accept the board’s proposal for restructuring of the company and transfer of the Company’s projects regarding development of DNA-vaccines against hepatitis B and hepatitis C in accordance with the Term Sheet, which was put forward at the EGM and which earlier has been attached to the notice for the EGM.
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Mobile phone: +46 709 28 05 28
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.